Using whole exome sequencing to identify genetic markers for carboplatin and gemcitabine-induced toxicities.
Authors
Green, HHasmats, J
Kupershmidt, I
Edsgard, D
de Petris, L
Lewensohn, R
Blackhall, Fiona H
Vikingsson, S
Besse, B
Lindgren, A
Koyi, H
Branden, E
Peterson, C
Lundeberg, J
Affiliation
Medical and Health Sciences, Linkoping UniversityIssue Date
2015-09-16
Metadata
Show full item recordAbstract
Chemotherapies are associated with significant inter-individual variability in therapeutic effect and adverse drug reactions. In lung cancer, the use of gemcitabine and carboplatin induces grade 3 or 4 myelosuppression in about a quarter of the patients, while an equal fraction of patients are basically unaffected in terms of myelosuppressive side effects. We therefore set out to identify genetic markers for gemcitabine/carboplatin-induced myelosuppression.Citation
Using whole exome sequencing to identify genetic markers for carboplatin and gemcitabine-induced toxicities. 2015: Clin Cancer ResJournal
Clinical Cancer ResearchDOI
10.1158/1078-0432.CCR-15-0964PubMed ID
26378035Type
ArticleLanguage
enISSN
1078-0432ae974a485f413a2113503eed53cd6c53
10.1158/1078-0432.CCR-15-0964
Scopus Count
Collections
Related articles
- Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia.
- Authors: Björn N, Sigurgeirsson B, Svedberg A, Pradhananga S, Brandén E, Koyi H, Lewensohn R, de Petris L, Apellániz-Ruiz M, Rodríguez-Antona C, Lundeberg J, Gréen H
- Issue date: 2020 Apr
- Genetic association of gemcitabine/carboplatin-induced leukopenia and neutropenia in non-small cell lung cancer patients using whole-exome sequencing.
- Authors: Svedberg A, Björn N, Sigurgeirsson B, Pradhananga S, Brandén E, Koyi H, Lewensohn R, De Petris L, Apellániz-Ruiz M, Rodríguez-Antona C, Lundeberg J, Gréen H
- Issue date: 2020 Sep
- Whole-genome sequencing and gene network modules predict gemcitabine/carboplatin-induced myelosuppression in non-small cell lung cancer patients.
- Authors: Björn N, Badam TVS, Spalinskas R, Brandén E, Koyi H, Lewensohn R, De Petris L, Lubovac-Pilav Z, Sahlén P, Lundeberg J, Gustafsson M, Gréen H
- Issue date: 2020 Aug 24
- Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma.
- Authors: Hainsworth JD, Burris HA 3rd, Erland JB, Morrissey LH, Meluch AA, Kalman LA, Hon JK, Scullin DC Jr, Smith SW, Greco FA
- Issue date: 1999 Mar 15
- Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma.
- Authors: Gajra A, Mehdi SA, Kirshner J, Newman N, Graziano SL
- Issue date: 2001 May